The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.
Right arrow Articles by Yang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.
Right arrow Articles by Yang, Y.
The Journal of Immunology, 2005, 175: 4283-4291.
Copyright © 2005 by The American Association of Immunologists

Protection against Autoimmunity in Nonlymphopenic Hosts by CD4+CD25+ Regulatory T Cells Is Antigen-Specific and Requires IL-10 and TGF-{beta}1

Xiaopei Huang, Jiangao Zhu and Yiping Yang2

Departments of Medicine and Immunology, Duke University Medical Center, Durham, NC 27710

CD4+CD25+ regulatory T cells (TReg) play a critical role in the control of autoimmunity. However, little is known about how TReg suppress self-reactive T cells in vivo, thus limiting the development of TReg-based therapy for treating autoimmune diseases. This is in large part due to the dependency on a state of lymphopenia to demonstrate TReg-mediated suppression in vivo and the unknown Ag specificity of TReg in most experimental models. Using a nonlymphopenic model of autoimmune pneumonitis and TReg with known Ag specificity, in this study we demonstrated that these TReg can actively suppress activation of self-reactive T cells and protect mice from fatal autoimmune pneumonitis. The protection required TReg with the same Ag specificity as the self-reactive T cells and depended on IL-10 and TGF-{beta}. These results suggest that suppression of autoimmunity by TReg in vivo consists of multiple layers of regulation and advocate for a strategy involving Ag-specific TReg for treating organ-specific autoimmunity, because they do not cause generalized immune suppression.




This article has been cited by other articles:


Home page
J. Immunol.Home page
T. J. Harris, J. F. Grosso, H.-R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al.
Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity
J. Immunol., October 1, 2007; 179(7): 4313 - 4317.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Ochoa-Reparaz, C. Riccardi, A. Rynda, S. Jun, G. Callis, and D. W. Pascual
Regulatory T Cell Vaccination without Autoantigen Protects against Experimental Autoimmune Encephalomyelitis
J. Immunol., February 1, 2007; 178(3): 1791 - 1799.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, and T. R. Mosmann
T Regulatory and Primed Uncommitted CD4 T Cells Express CD73, Which Suppresses Effector CD4 T Cells by Converting 5'-Adenosine Monophosphate to Adenosine
J. Immunol., November 15, 2006; 177(10): 6780 - 6786.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.